{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:44:49Z","timestamp":1788882289099,"version":"build-2803163510"},"reference-count":354,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["PN-IV-P8-8.3-ROMD-2023-0036"],"award-info":[{"award-number":["PN-IV-P8-8.3-ROMD-2023-0036"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["101227725"],"award-info":[{"award-number":["101227725"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["101168810"],"award-info":[{"award-number":["101168810"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055-2-1"],"award-info":[{"award-number":["KO5055-2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO5055\/3-1"],"award-info":[{"award-number":["KO5055\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["409510"],"award-info":[{"award-number":["409510"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"Hector Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Deutsche Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung eV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018712","name":"Universitatea de Medicin\u0103 \u015fi Farmacie Iuliu Ha\u0163ieganu Cluj-Napoca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"Elite Network of Bavaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bavarian Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["955575"],"award-info":[{"award-number":["955575"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013294","name":"Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Umwelt und Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008769","name":"Abt Global","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["SFB-TRR 338\/1 2021\\u2013452881907"],"award-info":[{"award-number":["SFB-TRR 338\/1 2021\\u2013452881907"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CoG 101124203"],"award-info":[{"award-number":["CoG 101124203"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101100460"],"award-info":[{"award-number":["101100460"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["756017"],"award-info":[{"award-number":["756017"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010138","name":"Fritz Bender Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research and Innovation","doi-asserted-by":"publisher","award":["PN-IV-P8-8.3-ROMD-2023-0036"],"award-info":[{"award-number":["PN-IV-P8-8.3-ROMD-2023-0036"]}],"id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018987","name":"Romanian Government Ministry of Research and Innovation","doi-asserted-by":"publisher","award":["PN-IV-P2-2.1-TE-2023-0483"],"award-info":[{"award-number":["PN-IV-P2-2.1-TE-2023-0483"]}],"id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR 1089 2024-2026"],"award-info":[{"award-number":["PNRR 1089 2024-2026"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["760278\/26.03.2024"],"award-info":[{"award-number":["760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.blre.2025.101354","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:41:45Z","timestamp":1764175305000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases"],"prefix":"10.1016","volume":"75","author":[{"given":"Adrian-Bogdan","family":"Tigu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin-Sorin","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kegyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena","family":"Muresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Feder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Jitaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Santa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Damian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Ivancuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Bojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Dana","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1186\/s12889-024-19290-3","article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15-39 years): an analysis based on the global burden of disease study 2021","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101354_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00139","article-title":"The autoimmune ecology","volume":"7","author":"Anaya","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102266","article-title":"The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0030","article-title":"Early and differential autoimmune diseases diagnosis by interrogating specific autoantibody signatures with multiplexed electrochemical bioplatforms","volume":"13","author":"Ar\u00e9valo","year":"2023","journal-title":"Biosens Bioelectron: X"},{"issue":"Supplement 2","key":"10.1016\/j.blre.2025.101354_bb0035","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jaci.2009.09.041","article-title":"Diagnostic testing and interpretation of tests for autoimmunity","volume":"125","author":"Castro","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102386","article-title":"Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios","volume":"18","author":"Bossuyt","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0055","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-8529(05)70189-4","article-title":"Thyroid autoantibodies","volume":"30","author":"Saravanan","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humimm.2003.09.013","article-title":"Pathogenesis of diseases associated with antineutrophil cytoplasm autoantibodies","volume":"65","author":"Reumaux","year":"2004","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0065","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1523-1755.2000.057003846.x","article-title":"Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features","volume":"57","author":"Savige","year":"2000","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/clin.1994.1018","article-title":"Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes","volume":"70","author":"Shibata","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.111219","article-title":"The role and research progress of ACPA in the diagnosis and pathological mechanism of rheumatoid arthritis","volume":"86","author":"Cheng","year":"2025","journal-title":"Hum Immunol"},{"issue":"22","key":"10.1016\/j.blre.2025.101354_bb0080","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.blre.2025.101354_bb0085","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.3390\/ijms25147666","article-title":"Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies","volume":"25","author":"Yasmeen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101354_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147447","article-title":"Differential impact of environmental factors on systemic and localized autoimmunity","volume":"14","author":"Touil","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0105","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4049\/jimmunol.163.6.3153","article-title":"Role of the costimulatory molecule CD28 in the development of lupus in MRL\/lpr mice","volume":"163","author":"Tada","year":"1999","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0110","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/eji.1830261008","article-title":"Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2","volume":"26","author":"Webb","year":"1996","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00296-009-1249-0","article-title":"The effects of PDL-Ig on collagen-induced arthritis","volume":"31","author":"Wang","year":"2011","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gutjnl-2014-307311","article-title":"Protective effects of Fc-fused PD-L1 on two different animal models of colitis","volume":"64","author":"Song","year":"2015","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183726","article-title":"Tumor necrosis factor-\u03b1 blockade treatment decreased CD154 (CD40-ligand) expression in rheumatoid arthritis","volume":"12","author":"Tung","year":"2017","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0130","first-page":"1035","article-title":"Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes","volume":"26","author":"Harigai","year":"1999","journal-title":"J Rheumatol"},{"issue":"489","key":"10.1016\/j.blre.2025.101354_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humimm.2012.07.044","article-title":"Associations between TNFSF4 and TRAF1-C5 gene polymorphisms and systemic lupus erythematosus: a meta-analysis","volume":"73","author":"Lee","year":"2012","journal-title":"Hum Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0145","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2010.141838","article-title":"A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort","volume":"70","author":"Bossini-Castillo","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2025.101354_bb0150","author":"InformedHealth.org"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0155","first-page":"287","article-title":"Advancements in targeted therapies for autoimmune diseases: a review of recent clinical trials","volume":"19","author":"Wilshon","year":"2024","journal-title":"Int J Clin Rheumtol"},{"key":"10.1016\/j.blre.2025.101354_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1249500","article-title":"Novel and potential future therapeutic options in systemic autoimmune diseases","volume":"15","author":"Balogh","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0165","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101354_bb0170","series-title":"Clinical immunology","first-page":"677","article-title":"50 - Mechanisms of autoimmunity","author":"Antiochos","year":"2019"},{"key":"10.1016\/j.blre.2025.101354_bb0175","series-title":"T lymphocytes in autoimmunity","author":"Ruiz-Arg\u00fcelles","year":"2013"},{"issue":"5373","key":"10.1016\/j.blre.2025.101354_bb0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1126\/science.281.5373.96","article-title":"Visualization of specific B and T lymphocyte interactions in the lymph node","volume":"281","author":"Garside","year":"1998","journal-title":"Science"},{"issue":"6352","key":"10.1016\/j.blre.2025.101354_bb0185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/354389a0","article-title":"Intraclonal generation of antibody mutants in germinal centres","volume":"354","author":"Jacob","year":"1991","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0190","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/eji.1830241020","article-title":"Development of antibody diversity in single germinal centers: selective expansion of high-affinity variants","volume":"24","author":"Ziegner","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0195","series-title":"Self-tolerance and its loss","author":"Janeway","year":"2001"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01034-5","article-title":"Current advancements in cellular immunotherapy for autoimmune disease","volume":"47","author":"Berry","year":"2025","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0210","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"10379","key":"10.1016\/j.blre.2025.101354_bb0220","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101354_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"10416","key":"10.1016\/j.blre.2025.101354_bb0230","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0235","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0240","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0245","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.2007.071662","article-title":"Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study","volume":"67","author":"Karlson","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0250","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2014-205459","article-title":"Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study","volume":"73","author":"Lu","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.38201","article-title":"Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"66","author":"Reynisdottir","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7771","key":"10.1016\/j.blre.2025.101354_bb0260","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41586-019-1471-1","article-title":"Locally renewing resident synovial macrophages provide a protective barrier for the joint","volume":"572","author":"Culemann","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2025.101354_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.680043","article-title":"The therapeutic landscape of rheumatoid arthritis: current state and future directions","volume":"12","author":"Shams","year":"2021","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.blre.2025.101354_bb0275","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101354_bb0280","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0285","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0290","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the global burden of disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0295","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0300","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3749","article-title":"Incidence of type 1 diabetes mellitus in children and adolescents under 20 years of age across 55 countries from 2000 to 2022: a systematic review with meta-analysis","volume":"40","author":"Hormaz\u00e1bal-Aguayo","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"issue":"10035","key":"10.1016\/j.blre.2025.101354_bb0310","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(16)30582-7","article-title":"Genetic risk factors for type 1 diabetes","volume":"387","author":"Pociot","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0315","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.blre.2025.101354_bb0320","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra0808284","article-title":"Genetics of type 1A diabetes","volume":"360","author":"Concannon","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0325","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0330","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaut.2006.04.003","article-title":"Enteral virus infections in early childhood and an enhanced type 1 diabetes-associated antibody response to dietary insulin","volume":"27","author":"M\u00e4kel\u00e4","year":"2006","journal-title":"J Autoimmun"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0335","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00125-019-4942-x","article-title":"Early-life factors contributing to type 1 diabetes","volume":"62","author":"Craig","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.blre.2025.101354_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737964","article-title":"Environmental determinants of type 1 diabetes: from association to proving causality","volume":"12","author":"Quinn","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0345","doi-asserted-by":"crossref","first-page":"itc33","DOI":"10.7326\/AITC202203150","article-title":"Type 1 diabetes mellitus","volume":"175","author":"Syed","year":"2022","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0350","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0355","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dci18-0023","article-title":"Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association","volume":"41","author":"Chiang","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.blre.2025.101354_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h5441","article-title":"Development and validation of risk prediction equations to estimate future risk of blindness and lower limb amputation in patients with diabetes: cohort study","volume":"351","author":"Hippisley-Cox","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.blre.2025.101354_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075681","article-title":"New advances in type 1 diabetes","volume":"384","author":"Subramanian","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0370","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/dme.13941","article-title":"Non-insulin treatments for type 1 diabetes: critical appraisal of the available evidence and insight into future directions","volume":"36","author":"Wright","year":"2019","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0375","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00125-017-4377-1","article-title":"Regulatory T cell dysfunction in type 1 diabetes: what\u2019s broken and how can we fix it?","volume":"60","author":"Hull","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.blre.2025.101354_bb0380","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 diabetes: a chronic anti-self-inflammatory response","volume":"8","author":"Clark","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.958430","article-title":"Immunological balance between Treg and Th17 lymphocytes as a key element of type 1 diabetes progression in children","volume":"13","author":"Starosz","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0390","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/dbi20-0026","article-title":"Modulation of leukocytes of the innate arm of the immune system as a potential approach to prevent the onset and progression of type 1 diabetes","volume":"70","author":"Petrelli","year":"2021","journal-title":"Diabetes"},{"issue":"14","key":"10.1016\/j.blre.2025.101354_bb0395","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"issue":"16","key":"10.1016\/j.blre.2025.101354_bb0400","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1212\/WNL.0000000000005331","article-title":"Temporal trends in multiple sclerosis prevalence and incidence in a large population","volume":"90","author":"Rotstein","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0405","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis","year":"2015","journal-title":"Lancet Neurol"},{"issue":"6578","key":"10.1016\/j.blre.2025.101354_bb0410","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0415","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0420","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028944","article-title":"Lifestyle and environmental factors in multiple sclerosis","volume":"9","author":"Alfredsson","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00415-020-10119-8","article-title":"An atlas on risk factors for multiple sclerosis: a Mendelian randomization study","volume":"268","author":"Yuan","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.blre.2025.101354_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00425","article-title":"The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities","volume":"8","author":"Parnell","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0435","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1474-4422(22)00255-1","article-title":"Genetics of multiple sclerosis: lessons from polygenicity","volume":"21","author":"Goris","year":"2022","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.blre.2025.101354_bb0440","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.3390\/jcm13195687","article-title":"Picturing the multiple sclerosis patient journey: a symptomatic overview","volume":"13","author":"Correia","year":"2024","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0445","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0450","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1389201015666140617104332","article-title":"Current and future therapies targeting the immune system in multiple sclerosis","volume":"15","author":"Loleit","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0455","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","article-title":"Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm","volume":"32","author":"Cree","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0460","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/joim.13215","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis","volume":"289","author":"Piehl","year":"2021","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0465","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.27029","article-title":"The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases","volume":"96","author":"Brittain","year":"2024","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0470","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1007\/s00415-024-12642-4","article-title":"Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review","volume":"271","author":"Konitsioti","year":"2024","journal-title":"J Neurol"},{"issue":"17","key":"10.1016\/j.blre.2025.101354_bb0475","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"issue":"10441","key":"10.1016\/j.blre.2025.101354_bb0480","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0485","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0490","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0495","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.25497","article-title":"Environmental risk factors for systemic lupus erythematosus through the lens of social determinants of health","volume":"77","author":"Kim","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0500","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/joim.13448","article-title":"The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous","volume":"291","author":"Woo","year":"2022","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0505","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.berh.2017.09.005","article-title":"Understanding the role of environmental factors in the development of systemic lupus erythematosus","volume":"31","author":"Parks","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36901-y","article-title":"Environmental risk factors of systemic lupus erythematosus: a case\u2013control study","volume":"13","author":"Refai","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101354_bb0515","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.molimm.2024.10.005","article-title":"Deciphering cell-specific genetic insights: unraveling the immunogenetic landscape of systemic lupus erythematosus","volume":"175","author":"Zhang","year":"2024","journal-title":"Mol Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0520","article-title":"Investigation of the association between the genetic polymorphisms of the co-stimulatory system and systemic lupus erythematosus","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00281-021-00900-w","article-title":"Recent advances in understanding the genetic basis of systemic lupus erythematosus","volume":"44","author":"Ha","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.40674","article-title":"Brief report: how do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria","volume":"71","author":"Mosca","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl5","key":"10.1016\/j.blre.2025.101354_bb0535","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","article-title":"Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs","volume":"59","author":"Ruiz-Irastorza","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0540","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","article-title":"Pragmatic approaches to therapy for systemic lupus erythematosus","volume":"10","author":"Xiong","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101865","article-title":"New and future therapies: changes in the therapeutic armamentarium for SLE","volume":"37","author":"Askanase","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0550","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician\u2019s perspective","volume":"43","author":"Katarzyna","year":"2023","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0555","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0560","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/ijms26030929","article-title":"Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches","volume":"26","author":"Saegusa","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101354_bb0565","first-page":"247","article-title":"The epidemiology of Sj\u00f6gren\u2019s syndrome","volume":"6","author":"Patel","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0570","doi-asserted-by":"crossref","first-page":"A305","DOI":"10.1016\/j.autrev.2009.11.004","article-title":"The geoepidemiology of Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Mavragani","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0575","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","article-title":"Epidemiology of Sj\u00f6gren syndrome","volume":"20","author":"Beydon","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103673","article-title":"Sjogren\u2019s syndrome: everything you always wanted to know about genetic and epigenetic factors","volume":"23","author":"Perricone","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0585","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1038\/s41467-022-30773-y","article-title":"Genome-wide association study identifies Sj\u00f6gren\u2019s risk loci with functional implications in immune and glandular cells","volume":"13","author":"Khatri","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101354_bb0590","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823659","article-title":"The role of virus infections in Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Maslinska","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0595","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/joim.12888","article-title":"Infections increase the risk of developing Sj\u00f6gren\u2019s syndrome","volume":"285","author":"Mofors","year":"2019","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2025.101354_bb0600","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1196\/annals.1384.003","article-title":"Autoimmune diseases and Sjogren\u2019s syndrome: an autoimmune exocrinopathy","volume":"1098","author":"Fox","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105406","article-title":"Current and future treatment in primary Sj\u00f6gren\u2019s syndrome - a still challenging development","volume":"89","author":"Ritter","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"13","key":"10.1016\/j.blre.2025.101354_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311179","article-title":"Outline of salivary gland pathogenesis of Sj\u00f6gren\u2019s syndrome and current therapeutic approaches","volume":"24","author":"Yura","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0615","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae247","article-title":"How to focus on autoantigen-specific lymphocytes: a review on diagnosis and treatment of Sjogren\u2019s syndrome","volume":"117","author":"Ming","year":"2025","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2025.101354_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren\u2019s syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0625","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40259-021-00505-7","article-title":"Targeted therapy for primary Sj\u00f6gren\u2019s syndrome: where are we now?","volume":"35","author":"Wang","year":"2021","journal-title":"Biodrugs"},{"issue":"10452","key":"10.1016\/j.blre.2025.101354_bb0630","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101354_bb0635","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2024.21","article-title":"Cell therapy in Sj\u00f6gren\u2019s syndrome: opportunities and challenges","volume":"26","author":"Lu","year":"2024","journal-title":"Expert Rev Mol Med"},{"issue":"18","key":"10.1016\/j.blre.2025.101354_bb0640","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.3390\/jcm12185873","article-title":"Current views on pathophysiology and potential therapeutic targets in Sj\u00f6gren\u2019s syndrome: a review from the perspective of viral infections, toll-like receptors, and long-noncoding RNAs","volume":"12","author":"Horai","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101354_bb0645","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren\u2019s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0650","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101354_bb0655","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.blre.2025.101354_bb0660","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","article-title":"Pathophysiology and immunological profile of myasthenia gravis and its subgroups","volume":"49","author":"Romi","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb0665","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0670","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1172\/JCI117112","article-title":"Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes","volume":"93","author":"Nicolle","year":"1994","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0675","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0680","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108672119","article-title":"Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study","volume":"119","author":"Chia","year":"2022","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0685","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a 151Pro\u2192Ala change in TNIP1 and to human leukocyte antigen-B*08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0690","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0695","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.26169","article-title":"Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease","volume":"90","author":"Handunnetthi","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.blre.2025.101354_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.02627","article-title":"Altered gut microbiota in myasthenia gravis","volume":"9","author":"Qiu","year":"2018","journal-title":"Front Microbiol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0705","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0710","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","article-title":"Myasthenia gravis","volume":"2","author":"Juel","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0715","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-0035-1558975","article-title":"Myasthenia gravis","volume":"35","author":"Gwathmey","year":"2015","journal-title":"Semin Neurol"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0720","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb0725","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/s41433-024-03133-x","article-title":"Treating myasthenia gravis beyond the eye clinic","volume":"38","author":"Jacob","year":"2024","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0730","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future","volume":"38","author":"Crisafulli","year":"2024","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0735","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41598-017-18307-9","article-title":"Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment","volume":"8","author":"Petrov","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0740","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0745","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0750","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2025.101354_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109058","article-title":"Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study","volume":"241","author":"Wang","year":"2022","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0760","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.blre.2025.101354_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715036","article-title":"Clinical efficacy and safety of eculizumab for treating myasthenia gravis","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0770","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/mus.28184","article-title":"Efgartigimod in refractory autoimmune myasthenia gravis","volume":"70","author":"Remijn-Nelissen","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.blre.2025.101354_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0780","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"24","author":"Habib","year":"2025","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb0785","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb0790","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.blre.2025.101354_bb0795","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0800","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0805","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12016-021-08868-z","article-title":"Clinical features, immunopathogenesis, and therapeutic strategies in vitiligo","volume":"61","author":"Wang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0810","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/ng.3680","article-title":"Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants","volume":"48","author":"Jin","year":"2016","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0815","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jid.2017.02.004","article-title":"Pigmentation traits, sun exposure, and risk of incident vitiligo in women","volume":"137","author":"Dunlap","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0825","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/1346-8138.15743","article-title":"Vitiligo: a focus on pathogenesis and its therapeutic implications","volume":"48","author":"Bergqvist","year":"2021","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0830","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00403-023-02661-y","article-title":"Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study","volume":"315","author":"Rios-Duarte","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.blre.2025.101354_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1055958","article-title":"Immunometabolism in the pathogenesis of vitiligo","volume":"13","author":"Lyu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0840","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: a comprehensive overview part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up","volume":"65","author":"Alikhan","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0845","article-title":"Videodermoscopic changes of the hair in vitiligo lesions in relation to disease duration","volume":"12","author":"Anbar","year":"2022","journal-title":"Dermatol Pract Concept"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb0850","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/jdv.15604","article-title":"Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis","volume":"33","author":"van Geel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9988","key":"10.1016\/j.blre.2025.101354_bb0855","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0860","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/phpp.12740","article-title":"UVB phototherapy in the treatment of vitiligo: state of the art and clinical perspectives","volume":"38","author":"Bouceiro Mendes","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb0865","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0870","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/ced.14435","article-title":"Vitiligo: an update on systemic treatments","volume":"46","author":"Searle","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0875","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15033","article-title":"Oral cyclosporine is effective in stabilizing active vitiligo: results of a randomized controlled trial","volume":"34","author":"Mehta","year":"2021","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0880","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.3390\/ijms24119749","article-title":"Etiopathogenesis and emerging methods for treatment of vitiligo","volume":"24","author":"Iwanowski","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0885","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","article-title":"Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors","volume":"24","author":"Cunningham","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0890","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11357-024-01317-7","article-title":"Acquired hemophilia A as a disease of the elderly: a comprehensive review of epidemiology, pathogenesis, and novel therapy","volume":"47","author":"Lehoczki","year":"2025","journal-title":"GeroScience"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0895","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/hae.14845","article-title":"Acquired haemophilia A: a 15-year population-based review of incidence rate, patient demographics and treatment outcomes","volume":"29","author":"Tian","year":"2023","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb0900","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.18611","article-title":"Acquired Haemophilia A in four north European countries: survey of 181 patients","volume":"201","author":"Lindahl","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0905","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/hae.15037","article-title":"Acquired haemophilia A in Finland: a nationwide study of incidence, treatment and outcomes","volume":"30","author":"Nummi","year":"2024","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0910","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.hoc.2021.07.007","article-title":"Acquired hemophilia A","volume":"35","author":"Pai","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0915","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1160\/TH13-05-0363","article-title":"Acquired haemophilia A: a 2013 update","volume":"110","author":"Franchini","year":"2013","journal-title":"Thromb Haemost"},{"issue":"13","key":"10.1016\/j.blre.2025.101354_bb0920","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jcmm.17741","article-title":"RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia","volume":"27","author":"Tigu","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb0925","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101354_bb0930","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-62703-339-8_24","article-title":"Nijmegen-Bethesda assay to measure factor VIII inhibitors","volume":"992","author":"Duncan","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0935","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/hematology.2023000461","article-title":"Immunotherapy of acquired hemophilia A","volume":"2023","author":"Tiede","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2025.101354_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2020.100021","article-title":"Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: results from a prospective study (ACQUI-7) in France","volume":"2","author":"Guillet","year":"2021","journal-title":"Thromb Update"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0945","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.thromres.2015.10.032","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study","volume":"136","author":"Zanon","year":"2015","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0950","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb0955","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb0960","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb0965","article-title":"The role of myositis-specific autoantibodies in the dermatomyositis spectrum","volume":"14","author":"Marasandra Ramesh","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.blre.2025.101354_bb0970","series-title":"Polymyositis","author":"da Sarwar","year":"2023"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb0975","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s13311-018-0658-8","article-title":"Inclusion body myositis: update on pathogenesis and treatment","volume":"15","author":"Naddaf","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.blre.2025.101354_bb0980","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019972","article-title":"Anti-SRP immune-mediated necrotizing myopathy: a critical review of current concepts","volume":"13","author":"Ma","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb0985","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb0990","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb0995","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/pde.14243","article-title":"Anti-Ku antibody-positive systemic sclerosis-polymyositis overlap syndrome in an adolescent","volume":"37","author":"Loo","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1000","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1005","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1020","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1136\/annrheumdis-2017-211174","article-title":"Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study","volume":"76","author":"Svensson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.rdc.2022.06.007","article-title":"Environmental risks for inflammatory myopathies","volume":"48","author":"Che","year":"2022","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.blre.2025.101354_bb1035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik","year":"2016","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1040","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/rheumatology\/keaf116","article-title":"Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review","volume":"64","author":"Paik","year":"2025","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/1744666X.2018.1491307","article-title":"Treatment of inflammatory myopathies","volume":"14","author":"Pipitone","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13311-015-0394-2","article-title":"Immunotherapies for immune-mediated myopathies: a current perspective","volume":"13","author":"Needham","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12016-016-8530-2","article-title":"Modern therapies for idiopathic inflammatory myopathies (IIMs): role of biologics","volume":"52","author":"Moghadam-Kia","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1060","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101981","article-title":"Insights into the genetic landscape of systemic sclerosis","volume":"38","author":"El-Halwagi","year":"2024","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.blre.2025.101354_bb1070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-3-030-92616-8_10","article-title":"The immunogenetics of systemic sclerosis","volume":"1367","author":"\u00dcnl\u00fc","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2025.101354_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102727","article-title":"Insights into the knowledge of complex diseases: environmental infectious\/toxic agents as potential etiopathogenetic factors of systemic sclerosis","volume":"124","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2025.101354_bb1080","series-title":"Infection and autoimmunity","first-page":"783","article-title":"Chapter 42 - infections and systemic sclerosis","author":"Balbir-Gurman","year":"2024"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kead699","article-title":"Steroid hormones in systemic sclerosis: associations with disease characteristics and modifications during scleroderma renal crisis","volume":"64","author":"Collet","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: clinical features and pathogenesis","volume":"87","author":"Jerjen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1095","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1100","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s10067-021-05665-z","article-title":"B cells in systemic sclerosis: from pathophysiology to treatment","volume":"40","author":"Melissaropoulos","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2010.11.005","article-title":"Management of Raynaud\u2019s phenomenon and digital ulcers in systemic sclerosis","volume":"78","author":"Botzoris","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101354_bb1115","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1182\/blood-2022-169265","article-title":"Safety and efficacy of CD19 CAR-T cells for refractory systemic sclerosis: a phase I clinical trial","volume":"140","author":"Feng","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1120","article-title":"Immunotherapy strategy for systemic autoimmune diseases: betting on CAR-T cells and antibodies","volume":"13","author":"Chasov","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/BOR.0000000000001012","article-title":"Chimeric antigen receptors: \u201cCARs\u201d in the fast lane for rheumatology","volume":"36","author":"Johnson","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1135","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2025.101354_bb1140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1564998","article-title":"Challenges in the preclinical design and assessment of CAR-T cells","volume":"16","author":"Tomai","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb1150","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc Natl Acad Sci"},{"issue":"15","key":"10.1016\/j.blre.2025.101354_bb1155","first-page":"3369","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb1165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities","volume":"112","author":"Ho","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1170","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1175","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2217\/imt.13.54","article-title":"Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer","volume":"5","author":"Hombach","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.blre.2025.101354_bb1185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1190","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2025.101354_bb1195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1205","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1210","doi-asserted-by":"crossref","first-page":"93","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1215","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb1220","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.blre.2025.101354_bb1225","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.blre.2025.101354_bb1230","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.blre.2025.101354_bb1235","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1240","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1245","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1250","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.blre.2025.101354_bb1255","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2025.101354_bb1265","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101354_bb1270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2025.101354_bb1275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb1280","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009174","article-title":"Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies","volume":"12","author":"Fleischer","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"26","key":"10.1016\/j.blre.2025.101354_bb1285","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2025.101354_bb1290","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186098","article-title":"Outcomes of CAR-T cell therapy recipients admitted to the ICU: in search for a standard of care-a brief overview and meta-analysis of proportions","volume":"12","author":"Constantinescu","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1295","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1300","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1305","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101354_bb1315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"20","key":"10.1016\/j.blre.2025.101354_bb1320","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5858\/arpa.2017-0278-RS","article-title":"Tumor lysis syndrome","volume":"143","author":"Williams","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.blre.2025.101354_bb1330","article-title":"Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1335","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","volume":"87","author":"Greenbaum","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.blre.2025.101354_bb1340","article-title":"CAR-based cell therapy for autoimmune diseases","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb1350","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61683","article-title":"Late adverse events after chimeric antigen receptor T-cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma","volume":"8","author":"Camacho-Arteaga","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1355","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1360","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","article-title":"Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy","volume":"96","author":"Vonberg","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1365","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"7971","key":"10.1016\/j.blre.2025.101354_bb1370","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"issue":"10480","key":"10.1016\/j.blre.2025.101354_bb1375","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0140-6736(25)00039-X","article-title":"Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells","volume":"405","author":"Baker","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.blre.2025.101354_bb1380","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-T-cell therapy: a review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb1385","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtct.2024.06.027","article-title":"Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma","volume":"30","author":"Lorenc","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.blre.2025.101354_bb1390","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1395","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jtct.2025.06.001","article-title":"Malignancies after chimeric antigen receptor T cell therapy","volume":"31","author":"Mohty","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.blre.2025.101354_bb1400","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1405","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.blre.2025.101354_bb1410","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1415","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1425","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","volume":"14","author":"Le Cacheux","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"35","key":"10.1016\/j.blre.2025.101354_bb1430","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"482","key":"10.1016\/j.blre.2025.101354_bb1435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1440","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1445","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603237","article-title":"Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment?","volume":"11","author":"Sadeqi Nezhad","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1450","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1455","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1460","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101354_bb1465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465191","article-title":"Application of novel CAR technologies to improve treatment of autoimmune disease","volume":"15","author":"Cheever","year":"2024","journal-title":"Front Immunol"},{"issue":"5, Supplement","key":"10.1016\/j.blre.2025.101354_bb1470","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.jcyt.2025.03.375","article-title":"Efficient cost-effective manufacture of a non-viral transposon based novel BAFF-cart for treatment of B-cell cancers","volume":"27","author":"Lawrence","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2025.101354_bb1475","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood-2021-150650","article-title":"Tri-specific CD19xCD20xCD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models","volume":"138","author":"Zhou","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1480","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.blre.2025.101354_bb1485","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162322","article-title":"Supercharged chimeric antigen receptor T cells in solid tumors","volume":"132","author":"Pant","year":"2022","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.blre.2025.101354_bb1490","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155621","article-title":"An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma","volume":"132","author":"Tian","year":"2022","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb1495","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","article-title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function","volume":"7","author":"Leung","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1500","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/bjh.19631","article-title":"Development of novel humanized CD19\/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms","volume":"205","author":"Wu","year":"2024","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2025.101354_bb1505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101354_bb1510","doi-asserted-by":"crossref","DOI":"10.37349\/ei.2025.1003185","article-title":"A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes\u2014a brief review","volume":"5","author":"Segovia","year":"2025","journal-title":"Explor Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1515","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14712598.2022.2026921","article-title":"Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from lupus","volume":"22","author":"Radic","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb1520","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/CM9.0000000000003111","article-title":"Dawn of CAR-T cell therapy in autoimmune diseases","volume":"137","author":"Liu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101354_bb1525","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2024-204169","article-title":"A study of Kyv-101, a CD19 CAR T cell therapy, in participants with treatment refractory progressive multiple sclerosis","volume":"144","author":"Seshadri","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2025.101354_bb1535","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1502298","article-title":"The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment","volume":"15","author":"Guo","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2025.101354_bb1540","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1363102","article-title":"Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells","volume":"15","author":"Dabkowska","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1545","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2538350","article-title":"Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases","volume":"21","author":"Jiang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1550","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.blre.2025.101354_bb1555","article-title":"Interferon activation in bone marrow long-lived plasma cells in systemic lupus erythematosus","volume":"15","author":"Alzamareh","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1560","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.blre.2025.101354_bb1565","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"20","key":"10.1016\/j.blre.2025.101354_bb1570","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1575","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1580","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1585","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb1590","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101354_bb1595","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1600","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.43","article-title":"Treg activation defect in type 1 diabetes: correction with TNFR2 agonism","volume":"5","author":"Okubo","year":"2016","journal-title":"Clin Transl Immunol"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1605","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1610","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2019.00159","article-title":"The regulatory T cell in active systemic lupus erythematosus patients: a systemic review and meta-analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1620","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.blre.2025.101354_bb1625","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1630","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/08916930903541190","article-title":"T regulatory cells lacking CD25 are increased in MS during relapse","volume":"43","author":"Fransson","year":"2010","journal-title":"Autoimmunity"},{"issue":"45","key":"10.1016\/j.blre.2025.101354_bb1635","doi-asserted-by":"crossref","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis","volume":"106","author":"Wright","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1640","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.4049\/jimmunol.178.11.6725","article-title":"Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta","volume":"178","author":"Xu","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1645","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.blre.2025.101354_bb1650","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2025.101354_bb1655","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-MON-LB033","article-title":"MON-LB033 unleashing the anti-inflammatory potential of Treg cells against type I diabetes using advanced chimeric antigen receptor technology","volume":"3","author":"Imam","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.blre.2025.101354_bb1660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by Tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.blre.2025.101354_bb1665","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.blre.2025.101354_bb1670","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1016\/j.cell.2024.07.056","article-title":"Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases","volume":"187","author":"Baker","year":"2024","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.blre.2025.101354_bb1675","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1016\/j.ymthe.2025.05.030","article-title":"A novel CD3epsilon fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape","volume":"33","author":"Lu","year":"2025","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.blre.2025.101354_bb1680","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101354_bb1685","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3324\/haematol.2023.284604","article-title":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Locatelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101354_bb1690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1199145","article-title":"Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy","volume":"14","author":"Lv","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2025.101354_bb1695","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CJI.0000000000000552","article-title":"Combined CLEC2d expression and CD58 loss mitigate rejection of allogeneic T cells","volume":"48","author":"Coholan","year":"2025","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1700","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41467-024-44786-2","article-title":"Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vbeta2+ T cell malignancy","volume":"15","author":"Ren","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.blre.2025.101354_bb1705","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"16","key":"10.1016\/j.blre.2025.101354_bb1710","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.blre.2025.101354_bb1715","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","article-title":"Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus","volume":"84","author":"Fu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.blre.2025.101354_bb1720","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"6753","key":"10.1016\/j.blre.2025.101354_bb1725","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.blre.2025.101354_bb1730","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2025.101354_bb1735","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1740","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2558403","article-title":"In vivo CAR-T cell therapy: new breakthroughs for cell-based tumor immunotherapy","volume":"21","author":"Huang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.1016\/j.blre.2025.101354_bb1745","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101354_bb1750","article-title":"The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.blre.2025.101354_bb1755","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-24-2668","article-title":"The CD70-CD27 axis in cancer immunotherapy: predictive biomarker and therapeutic target","volume":"31","author":"Sam","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2025.101354_bb1760","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102555","article-title":"CD70-targeted CAR-T\/NK therapy: rationale, advances, and future directions","volume":"62","author":"Yan","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.blre.2025.101354_bb1765","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.blre.2025.101354_bb1770","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:02:52Z","timestamp":1777539772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":354,"alternative-id":["S0268960X25000992"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101354","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101354"}}